Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma

BRAF and RAS are the most frequently mutated mitogen-activated protein kinase (MAPK) genes in melanoma. Binimetinib is a highly selective MAPK kinase (MEK) 1/2 inhibitor with clinical antitumor activity in NRAS- and BRAF(V600)-mutant melanoma. We performed a nonrandomized, open-label phase II study,...

Descripción completa

Detalles Bibliográficos
Autores principales: van Herpen, Carla M.L., Agarwala, Sanjiv S., Hauschild, Axel, Berking, Carola, Beck, J. Thaddeus, Schadendorf, Dirk, Jansen, Rob, Queirolo, Paola, Ascierto, Paolo A., Blank, Christian U., Heinrich, Michael C., Pal, Rupam R., Derti, Adnan, Antona, Victor, Nauwelaerts, Heidi, Zubel, Angela, Dummer, Reinhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2019
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442999/
https://www.ncbi.nlm.nih.gov/pubmed/30956763
http://dx.doi.org/10.18632/oncotarget.26753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6442999/
https://www.ncbi.nlm.nih.gov/pubmed/30956763
http://dx.doi.org/10.18632/oncotarget.26753

Ejemplares similares